Key Takeaways
- Lab studies link short sleep to extra eating, mostly late at night.
- The hormone ghrelin, which signals hunger, tends to rise with short sleep.
- Grades tracked sleep over weeks and months, not the night before a test.
- Teens need nine to 10 hours, and adults need seven or more.
- Zepbound, not Mounjaro, is approved for moderate to severe obstructive sleep apnea in adults with obesity.
Lack of sleep does not add weight on its own, but it reliably raises eating, mostly late at night, which can add weight over time.
For students, the sleep that protects grades also protects appetite. Short sleep changes hunger hormones, evening cortisol, and testosterone. Weight gain can worsen sleep apnea.
Sleep and Exam Performance
In a study of 88 college chemistry students who wore sleep trackers, longer and more regular sleep over the previous week and month tracked better grades. Sleep on the single night before a test did not.
In a diary study of 535 high school students, nights when students cut sleep to study more were followed by more trouble understanding class and more struggles on tests the next day.
In a survey of 120 college students, 60% had pulled at least one all-nighter. Those students had lower grade point averages, but the survey cannot show cause.
Pooled experiments find that a full night without sleep harms memory, especially when it comes before learning. Many of the studies were small.
How Sleep Loss Changes Hunger Hormones (Ghrelin, Leptin)
Sleep loss tends to raise ghrelin, a hormone that signals hunger. Its effect on leptin, a hormone that signals fullness, is mixed.
In a lab study of 12 young men, two nights of four hours in bed lowered leptin by 18%, raised ghrelin by 28%, and raised hunger by about a quarter. The rise in hunger was largest for sweet and starchy foods.
Leptin has fallen in some studies, stayed flat in others, and risen in pooled sleep deprivation studies.
Hormones do not fully explain why people eat more after short sleep.
Late-Night Cravings and Weight Gain
Short sleep can contribute to weight gain because people eat more, mostly late at night.
Pooled sleep restriction experiments found that people ate about 385 more calories a day without burning more.
In a lab study of 225 adults, five nights of four hours in bed led to about 550 extra calories eaten between 10 p.m. and 4 a.m. The short sleepers gained about two pounds, versus about 0.2 pounds for normal sleepers.
Brain scans after a sleepless night show weaker activity in planning areas, stronger activity in reward areas, and a stronger pull toward high-calorie foods.
Short sleepers are about one and a half times as likely to have obesity in pooled population studies. These studies show a link, not a cause.
In a randomized trial of 80 overweight adults who usually slept less than six and a half hours, coaching to sleep about one hour longer cut intake by about 270 calories a day over two weeks.
Stress, Cortisol, and Sleep
Stress can shorten sleep, and short sleep can raise the stress hormone cortisol.
A review of studies on work stress found that worrying about a demanding next day, such as an exam day, appears to be an important link between stress and poor sleep.
In a lab study of young men, one short or sleepless night raised cortisol the next evening by 37% to 45%.
A week of five-hour nights left daytime cortisol unchanged in another lab study. The rise is clearest in the evening.
Sleep and Testosterone
Short sleep can lower testosterone in young men. Most of a man's daily testosterone release happens during sleep.
In a lab study of 10 young men, a week of five-hour nights lowered daytime testosterone by 10% to 15%. The researchers compared that drop to years of normal aging. The men also reported less vigor.
Men with sleep apnea tend to have lower testosterone, especially with severe apnea. Treating the apnea with a breathing machine has not raised testosterone in pooled studies.
How Much Sleep Adults and Students Need
Teens need nine to 10 hours of sleep, and adults from age 18 need seven or more hours on a regular basis.
College students fall under the adult guidance. More than nine hours may suit young adults and people recovering from lost sleep.
Regularly sleeping less than seven hours is linked to weight gain and obesity, diabetes, high blood pressure, heart disease, stroke, and depression.
Sleep Apnea and Weight: Zepbound (Tirzepatide), FDA-Approved for Moderate to Severe Obstructive Sleep Apnea in Adults With Obesity
Zepbound is approved to treat moderate to severe obstructive sleep apnea in adults with obesity, with a reduced-calorie diet and increased physical activity. The FDA approved this use in December 2024.
Obstructive sleep apnea happens when the upper airway becomes blocked during sleep, causing pauses in breathing. In people with obesity, fat deposits in the neck can block the airway.
In a four-year study of 690 adults, a 10% weight gain predicted about a 32% rise in breathing events per hour. A 10% weight loss predicted about a 26% drop.
Zepbound is also approved, with the same diet and activity changes, for long-term weight reduction in adults with obesity, or with overweight and at least one weight-related condition.
Mounjaro is the same drug, tirzepatide, approved for type 2 diabetes. Using Mounjaro for weight loss or sleep apnea is off-label.
Two 52-week randomized trials enrolled 469 adults with obesity, moderate to severe sleep apnea, and no type 2 diabetes. The results:
- Breathing events per hour fell by about 51% to 59% on tirzepatide, versus about 3% on placebo.
- About 42% to 50% on tirzepatide reached remission or mild sleep apnea without daytime sleepiness, versus 14% to 16% on placebo.
- Body weight fell by about 18% to 20% on tirzepatide.
The improvement in breathing is likely related to weight loss. The trials did not test whether people can stop using a breathing machine.
The boxed warning states that tirzepatide causes thyroid C-cell tumors in rats and that it is unknown whether it does in humans. People with a personal or family history of medullary thyroid carcinoma, or with multiple endocrine neoplasia syndrome type 2, must not use it.
Starting a prescription drug is the prescribing clinician's decision.
Tirzepatide and Sleep Side Effects (Some Users Report Insomnia)
Insomnia is not listed as a side effect in the Zepbound or Mounjaro labels.
A few public social media posts about tirzepatide mention insomnia. In an analysis of voluntary US adverse event reports, an insomnia-type sleep problem was reported more often than expected for tirzepatide. Such reports cannot show that the drug caused the problem.
In the sleep apnea trials, people on tirzepatide reported a larger drop in sleep disturbance than people on placebo.
The most common side effects in the labels are digestive, including nausea, diarrhea, vomiting, and constipation. Most nausea, vomiting, and diarrhea occurred while the dose was being raised and decreased over time.
Anyone with new sleep problems on tirzepatide can raise them with the prescriber.
Sources
- Sleep and exam performance: Okano et al., NPJ Sci Learn, 2019; Gillen-O'Neel et al., Child Dev, 2013; Thacher, Behav Sleep Med, 2008; Newbury et al., Psychol Bull, 2021
- Hunger hormones: Spiegel et al., Ann Intern Med, 2004; Nedeltcheva et al., Am J Clin Nutr, 2009; Lin et al., Obes Rev, 2020
- Late-night cravings and weight: Al Khatib et al., Eur J Clin Nutr, 2017; Spaeth et al., Sleep, 2013; Greer et al., Nat Commun, 2013; Cappuccio et al., Sleep, 2008; Tasali et al., JAMA Intern Med, 2022
- Stress, cortisol and sleep: Åkerstedt, Scand J Work Environ Health, 2006; Leproult et al., Sleep, 1997
- Sleep and testosterone: Leproult and Van Cauter, JAMA, 2011; Su et al., Andrology, 2022; Cignarelli et al., Front Endocrinol, 2019
- Sleep need: Paruthi et al., J Clin Sleep Med (AASM pediatric consensus), 2016; Watson et al., J Clin Sleep Med (AASM and SRS consensus), 2015; CDC About Sleep, 2024
- Sleep apnea, weight, and Zepbound: Zepbound label, 2026; FDA Approves First Medication for Obstructive Sleep Apnea, 2024; NHLBI Sleep Apnea Causes and Risk Factors, 2025; Peppard et al., JAMA, 2000; Mounjaro label, 2026; Malhotra et al., N Engl J Med (SURMOUNT-OSA), 2024
- Insomnia reports: Alibilli et al., JMIR Infodemiology, 2025; Gu, Drug Healthc Patient Saf, 2026
This article is for general information and does not provide medical advice.


